ID   CS-1 [Human chondrosarcoma]
AC   CVCL_T023
SY   Cs-1; CS1; CHSA cell line
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_T023
DR   Cell_Model_Passport; SIDM00199
DR   Cosmic; 1992322
DR   Cosmic-CLP; 1290795
DR   DepMap; ACH-002099
DR   EGA; EGAS00001000978
DR   GDSC; 1290795
DR   GEO; GSM1669710
DR   PharmacoDB; CS1_266_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54814518
RX   PubMed=12631627;
RX   PubMed=14637196;
RX   PubMed=19528443;
RX   PubMed=24866169;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.36%; East Asian, North=1.25%; East Asian, South=0%; South Asian=0%; European, North=68.97%; European, South=29.41% (PubMed=30894373).
CC   Derived from site: Metastatic; Bone, humerus; UBERON=UBERON_0000976.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 9
ST   D16S539: 13,14
ST   D5S818: 12
ST   D7S820: 10,11
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C2946; Chondrosarcoma
DI   ORDO; Orphanet_55880; Chondrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 22
//
RX   PubMed=12631627;
RA   Morioka H., Weissbach L., Vogel T., Nielsen G.P., Faircloth G.T.,
RA   Shao L., Hornicek F.J.;
RT   "Antiangiogenesis treatment combined with chemotherapy produces
RT   chondrosarcoma necrosis.";
RL   Clin. Cancer Res. 9:1211-1217(2003).
//
RX   PubMed=14637196; DOI=10.1016/j.bcp.2003.08.033;
RA   Shao L., Kasanov J., Hornicek F.J., Morii T., Fondren G.,
RA   Weissbach L.;
RT   "Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional
RT   and cellular alterations.";
RL   Biochem. Pharmacol. 66:2381-2395(2003).
//
RX   PubMed=19528443;
RA   Susa M., Morii T., Yabe H., Horiuchi K., Toyama Y., Weissbach L.,
RA   Hornicek F.J., Morioka H.;
RT   "Alendronate inhibits growth of high-grade chondrosarcoma cells.";
RL   Anticancer Res. 29:1879-1888(2009).
//
RX   PubMed=24866169; DOI=10.1158/2326-6066.CIR-13-0224;
RA   Shen J.K., Cote G.M., Choy E., Yang P., Harmon D., Schwab J.H.,
RA   Nielsen G.P., Chebib I., Ferrone S., Wang X.-H., Wang Y.-Y.,
RA   Mankin H.J., Hornicek F.J., Duan Z.-F.;
RT   "Programmed cell death ligand 1 expression in osteosarcoma.";
RL   Cancer Immunol. Res. 2:690-698(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//